Novartis loses in patent appeal over multiple sclerosis drug

Los Angeles A U.S. appeals court on Tuesday ruled against Swiss drugmaker Novartis AG in a patent infringement dispute concerning its blockbuster multiple sclerosis drug Gilenya. The U.S. Court of Appeals for the Federal Circuit, which hears patent appeals, reversed its own earlier ruling in the case. A divided panel found Novartis’ patent was invalid…
Read More